The chronic weekly 13-week treatment in JNPL3 tauopathy mice (10 mg/kg intraperitoneally) robustly cleared insoluble tau (59%–74% reduction), whereas soluble tau was not significantly affected. This evidence concerns the gene MAPT and tauopathy.